Celldex Therapeutics CLDX Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's quick ratio?
- Celldex Therapeutics (CLDX) reported quick ratio of 8.9× in Q1 2026.
- How has Celldex Therapeutics's quick ratio changed year-over-year?
- Celldex Therapeutics's quick ratio decreased by 58.8% year-over-year, from 21.7× to 8.9×.
- What is the long-term trend for Celldex Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Celldex Therapeutics's quick ratio has grown at a -5.5% compound annual growth rate (CAGR), from 13.9× to 10.5×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.